Page 29 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine FAP-targeted RLT in cancer

A B C D

E F G H

Figure 2. Radiology of a 25-year-old man diagnosed with nasopharyngeal carcinoma. (A) The F-FDG and Ga-FAPI-46 PET/CT images revealed
68
18
multiple lymph node and bone metastases, and Ga-FAPI-46 PET/CT showed a greater number of metastatic lesions than F-FDG in July 2020. Due to
68
18
the lack of other available treatment choices, the patient participated in a clinical trial for Lu-FAPI-46 radionuclide therapy (NCT04849247). (B–D) A
177
68 Ga-FAPI-46 PET/CT was performed before radionuclide treatment, which showed intense radiotracer uptakes in most metastatic lesions. (E) Intense
177 Lu-FAPI-46 uptake was observed in most metastatic lesions on post-therapeutic scintigraphy at 2 h post-injection. (F–H) Follow-up Ga-FAPI-46
68
PET/CT was performed 8 weeks after radionuclide therapy, which showed a mixed response: regression in some lesions but progressive disease in other
lesions . Image reprinted with permission, Copyright © 2022, Kaili Fu et al.
[34]
Abbreviations: PET: Positron emission tomography; FAPI: Fibroblast activation protein inhibitor; FDG: Fluorodeoxyglucose; MIP: Maximum intensity
projection; PET/CT: Positron emission tomography/computed tomography.
related systemic immune suppression . Similar to EBRT, linear energy transfer . However, unlike EBRT, TRT can
[64]
[61]
TRT can also induce DNA double-strand breaks through be administered systemically to reach multiple metastatic
radiation effects because of its ability to deposit higher lesions throughout the body and exert therapeutic effects
energy within a shorter particle range, resulting in higher through radiation .
[65]
Volume 1 Issue 2 (2023) 8 https://doi.org/10.36922/arnm.1667